Andrew A Wagner

List of Publications by Year
in descending order

146 papers	5,599 citations	81839 39 h-index	88593 70 g-index
147 all docs	147 docs citations	147 times ranked	7200 citing authors

#	Article	IF	Citations
1	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. New England Journal of Medicine, 2015, 373, 428-437.	13.9	438
2	Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology, 2010, 28, 835-840.	0.8	362
3	Five-year Analysis of a Multi-institutional Prospective Clinical Trial of Delayed Intervention and Surveillance for Small Renal Masses: The DISSRM Registry. European Urology, 2015, 68, 408-415.	0.9	282
4	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	6.3	273
5	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer, 2012, 118, 1649-1655.	2.0	222
6	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. JAMA - Journal of the American Medical Association, 2020, 323, 1266.	3.8	190
7	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer, 2017, 123, 3285-3290.	2.0	170
8	Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors. Clinical Cancer Research, 2011, 17, 871-879.	3.2	150
9	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factorâ€“associated tumors. Cancer, 2012, 118, 5894-5902.	2.0	140
10	Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Modern Pathology, 2013, 26, 289-294.	2.9	134
11	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.2	122
12	Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 2874-2884.	3.2	103
13	Antiproliferative Effects of CDK4/6 Inhibition inCDK4-Amplified Human LiposarcomaIn VitroandIn Vivo. Molecular Cancer Therapeutics, 2014, 13, 2184-2193.	1.9	102
14	Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma. Cancer Research, 2010, 70, 639-645.	0.4	100
15	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	2.0	96
16	A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. European Journal of Cancer, 2017, 76, 144-151.	1.3	92
17	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of Clinical Oncology, 2020, 38, 1693-1701.	0.8	86
18	A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas. Clinical Cancer Research, 2013, 19, 6020-6029.	3.2	80

#	Article	IF	Citations
19	Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. Clinical Therapeutics, 2016, 38, 778-793.	1.1	79
20	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	0.8	78
21	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nature Communications, 2016, 7, 12609.	5.8	73
22	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational New Drugs, 2020, 38, 831-843.	1.2	71
23	nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology, 2021, 39, 3660-3670.	0.8	69
24	Imaging Features of Primary and Metastatic Malignant Perivascular Epithelioid Cell Tumors. American Journal of Roentgenology, 2014, 202, 252-258.	1.0	68
25	Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. BJU International, 2019, 123, 42-50.	1.3	65
26	A comparative propensity scoreâ€matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robotâ€assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU International, 2020, 126, 265-272.	1.3	64
27	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. JAMA Oncology, 2018, 4, e180219.	3.4	63
28	A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1044-1051.	3.2	61
29	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology, 2017, 72, 448-454.	0.9	61
30	Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget, 2016, 7, 16581-16592.	0.8	57
31	A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention. Journal of Urology, 2016, 196, 1356-1362.	0.2	51
32	Characteristics of mismatch repair deficiency in sarcomas. Modern Pathology, 2019, 32, 977-987.	2.9	49
33	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canaryâ€“Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology, 2015, 68, 1083-1088.	0.9	48
34	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer and Prostatic Diseases, 2018, 21, 364-372.	2.0	48
35	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology, 2020, 38, 1549-1557.	0.8	48
36	Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Journal of Urology, 2017, 197, 1427-1436.	0.2	47

#	Article	IF	Citations
37	Cost comparison of robotic, laparoscopic, and open partial nephrectomy.. Journal of Clinical Oncology, 2012, 30, 394-394.	0.8	47
38	CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. Molecular Cancer Therapeutics, 2015, 14, 1346-1353.	1.9	44
39	Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors. American Journal of Roentgenology, 2016, 206, 544-553.	1.0	41
40	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific Reports, 2019, 9, 14551.	1.6	41
41	Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncology, 2015, 51, 1026-1033.	0.8	39
42	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2019, 25, 7287-7293.	3.2	37
43	Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. Journal of Urology, 2021, 206, 80-87.	0.2	35
44	Biologic Activity of Autologous, Granulocyteâ€“Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	3.2	34
45	Robotic Surgery of the Kidney, Bladder, and Prostate. Surgical Clinics of North America, 2016, 96, 615-636.	0.5	34
46	Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. Journal of Urology, 2021, 205, 1286-1293.	0.2	33
47	Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry. Journal of Urology, 2015, 194, 903-909.	0.2	32
48	YWHAE -rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecologic Oncology, 2017, 145, 531-535.	0.6	32
49	Use of delayed intervention for small renal masses initially managed with active surveillance. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 18-25.	0.8	31
50	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	0.9	30
51	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	3.4	30
52	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2020, 203, 727-733.	0.2	30
53	Longâ€term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer, 2021, 127, 884-893.	2.0	29
54	Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. Journal of Urology, 2021, 205, 1689-1697.	0.2	29

#	Article	IF	Citations
55	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist, 2021, 26, e863-e873.	1.9	28
56	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. European Journal of Cancer, 2016, 61, 94-101.	1.3	25
57	Collaborating with our adult colleagues: A case series of robotic surgery for suspicious and cancerous lesions in children and young adults performed in a free-standing children's hospital. Journal of Pediatric Urology, 2018, 14, 182.e1-182.e8.	0.6	25
58	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer, 2020, 126, 98-104.	2.0	25
59	Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. Urology, 2016, 91, 143-149.	0.5	23
60	Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. Journal of Urology, 2017, 197, 109-114.	0.2	23
61	Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors. JAMA Oncology, 2021, 7, 1343.	3.4	23
62	The Challenge of Choosing Appropriate End Points in Single-Arm Phase II Studies of Rare Diseases. Journal of Clinical Oncology, 2012, 30, 896-898.	0.8	22
63	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	2.0	22
64	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical Cancer Research, 2021, 27, 3861-3866.	3.2	22
65	Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy. BMC Cancer, 2018, 18, 1296.	1.1	21
66	Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study. Modern Pathology, 2019, 32, 1158-1167.	2.9	21
67	Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC. Journal of Urology, 2020, 203, 57-61.	0.2	20
68	Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. World Journal of Urology, 2016, 34, 1651-1656.	1.2	19
69	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. European Urology, 2018, 73, 706-712.	0.9	17
70	Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Journal of Urology, 2021, 205, 407-413.	0.2	17
71	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. European Journal of Cancer, 2020, 126, 21-32.	1.3	16
72	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. Journal of Clinical Oncology, 2018, 36, 11502-11502.	0.8	16

#	Article	IF	Citations
73	Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 272.e1-272.e9.	0.8	16
74	Nonlinear microscopy for detection of prostate cancer: analysis of sensitivity and specificity in radical prostatectomies. Modern Pathology, 2020, 33, 916-923.	2.9	15
75	Selecting Patients with Small Renal Masses for Active Surveillance: A Domain Based Score from a Prospective Cohort Study. Journal of Urology, 2019, 201, 886-892.	0.2	15
76	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2022, 40, 2479-2490.	0.8	15
77	Development of a patient and institutionalâ€based model for estimation of operative times for robotâ€assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU International, 2017, 120, 695-701.	1.3	14
78	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clinical Cancer Research, 2019, 25, 5135-5142.	3.2	14
79	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. Journal of Clinical Pharmacology, 2020, 60, 605-616.	1.0	13
80	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 493-499.	1.2	13
81	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. Clinical Cancer Research, 2022, 28, 298-307.	3.2	12
82	The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 166.e17-166.e20.	0.8	11
83	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. Urology, 2019, 127, 53-60.	0.5	11
84	Reducing Pseudoaneurysm and Urine Leak After Robotic Partial Nephrectomy: Results Using the Early Unclamping Technique. Urology, 2019, 132, 130-135.	0.5	10
85	Incidence and preoperative predictors for major complications following radical nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1786-1793.	0.6	10
86	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncology, 2021, 17, 2923-2939.	1.1	10
87	International Radical Cystectomy Consortium: A way forward. Indian Journal of Urology, 2014, 30, 314.	0.2	10
88	Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1780-1785.	0.6	8
89	Misaligned Incentives in Benign Prostatic Enlargement Surgery: More Complex and Efficacious Procedures Are Earning Fewer Relative Value Units. Journal of Endourology, 2021, 35, 835-839.	1.1	8
90	Intracorporeal Versus Extracorporeal Neobladder After Robot-assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. Urology, 2022, 159, 127-132.	0.5	8

#	Article	IF	Citations
91	Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. Current Urology Reports, 2016, 17, 4.	1.0	7
92	Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men With Clinically Node-negative (cN0) Penile Cancer. Urology, 2021, 153, 221-227.	0.5	7
93	Exposureâ€“response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1422-1432.	1.3	7
94	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. Journal of Clinical Oncology, 2020, 38, 5503-5503.	0.8	7
95	Treatment of Advanced Soft Tissue Sarcoma: Conventional Agents and Promising New Drugs. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 401-410.	2.3	6
96	Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. JAMA Oncology, 2018, 4, 1169.	3.4	6
97	Reducing postoperative opioid pill prescribing via a quality improvement approach. International Journal for Quality in Health Care, 2021, 33, .	0.9	6
98	The potential of emerging new therapeutics for the treatment of perivascular epithelioid cell tumors (PEComa). Expert Opinion on Orphan Drugs, 2018, 6, 537-543.	0.5	5
99	Specific Targets in Sarcoma and Developmental Therapeutics. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 677-686.	2.3	4
100	Patientâ€derived sarcoma xenografts for individualâ€patient selection of chemotherapyâ€”ready for prime time?. Cancer, 2014, 120, 1917-1919.	2.0	4
101	Patient-Reported Quality of Life and Convalescence After Minimally Invasive Kidney Cancer Surgery. Urology, 2020, 144, 123-129.	0.5	4
102	Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e1-785.e10.	0.8	4
103	Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Journal of Endourology, 2021, 35, 1541-1547.	1.1	4
104	Continued 5Î±-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. Journal of Urology, 2019, 201, 106-112.	0.2	4
105	CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. Future Oncology, 2022, , .	1.1	4
106	Delayed Return of Ejaculatory Function in Adolescent Males Treated With Retroperitoneal Lymph Node Dissection and Adjuvant Therapy for Paratesticular Rhabdomyosarcoma. Urology, 2019, 124, 254-256.	0.5	3
107	The incidence, predictors, and survival of disappearing small renal masses on active surveillance. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 42.e1-42.e6.	0.8	3
108	Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution. BMC Urology, 2020, 20, 163.	0.6	3

#	Article	IF	Citations
109	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	2.0	3
110	Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).. Journal of Clinical Oncology, 2018, 36, 79-79.	0.8	3
111	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.2	3
112	Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robotâ€assisted radical cystectomy for muscleâ€invasive bladder cancer: Results from the International Robotic Cystectomy Consortium. International Journal of Urology, 2022, 29, 197-205.	0.5	3
113	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	1.3	3
114	MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.. Journal of Clinical Oncology, 2022, 40, TPS11590-TPS11590.	0.8	3
115	Targeted Therapy in Sarcoma: Should We Be Lumpers or Splitters?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 652-657.	1.8	2
116	Perceptions of Oncologists About Sharing Clinic Notes with Patients. Oncologist, 2019, 24, e46-e48.	1.9	2
117	Exposureâ€“response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. Expert Review of Clinical Pharmacology, 2021, 14, 927-935.	1.3	2
118	Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).. Journal of Clinical Oncology, 2017, 35, 11048-11048.	0.8	2
119	Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
120	MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.. Journal of Clinical Oncology, 2022, 40, TPS11589-TPS11589.	0.8	2
121	A phase 1b lead-in to a randomized phase 2 trial of lurbinectedin plus doxorubicin in leiomyosarcoma (LMS).. Journal of Clinical Oncology, 2022, 40, TPS11592-TPS11592.	0.8	2
122	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. Practical Radiation Oncology, 2018, 8, 445-451.	1.1	1
123	Perioperative Aspirin Use is Associated with Bleeding Complications During Robotic Partial Nephrectomy. Journal of Urology, 2021, , 101097JU0000000000002240.	0.2	1
124	Using Preoperative Pelvic Floor Assessment to Predict Early Return of Continence after Robotic Radical Prostatectomy. Urology, 2021, 155, 160-164.	0.5	1
125	Sterotactic body radiosurgery for primary small renal tumors: A retrospective analysis.. Journal of Clinical Oncology, 2014, 32, 475-475.	0.8	1
126	Real-world use of epic for clinical practice (EPIC-CP) to assess patient-reported prostate cancer quality of life in the clinical setting.. Journal of Clinical Oncology, 2015, 33, 18-18.	0.8	1

#	Article	IF	Citations
127	Trends in Sales Volumes of Cancer Medicines in Six Asian Countries Working Toward Universal Health Coverage. Journal of Global Oncology, 2018, 4, 220s-220s.	0.5	1
128	Societal costs after renal cancer surgery.. Journal of Clinical Oncology, 2015, 33, 512-512.	0.8	1
129	Immunohistochemical evaluation of p53, Ki67, ERG, MYC and PTEN in Gleason pattern 3 prostate cancer: Implication in active surveillance.. Journal of Clinical Oncology, 2018, 36, e17068-e17068.	0.8	1
130	Relapses Rates and Patterns for Pathological T0 after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Urology, 2022, , .	0.5	1
131	Distinct oncogenic signatures in malignant PEComa and leiomyosarcoma identified by integrative RNA-seq and H3K27ac ChIP-seq analysis.. Journal of Clinical Oncology, 2022, 40, 11552-11552.	0.8	1
132	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.2	1
133	Sarcoma. Hematology/Oncology Clinics of North America, 2013, 27, xi-xii.	0.9	0
134	An Unusual Presentation of Metastatic Urothelial Bladder Carcinoma With Rhabdoid Features Presenting as Obstructive Uropathy. Urology, 2018, 115, 33-35.	0.5	0
135	AUTHOR REPLY. Urology, 2019, 132, 135.	0.5	0
136	Editorial. Current Opinion in Urology, 2019, 29, 466-468.	0.9	0
137	Reply by Authors. Journal of Urology, 2021, 205, 1293-1293.	0.2	0
138	Prophylactic Mesh Placement at the Time of Ileal Conduit Creation: A Simple Sublay Technique. Videourology (New Rochelle, N Y), 2021, 35, .	0.1	0
139	A Novel High-Fidelity Robot-Assisted Radical Prostatectomy Simulator. Videourology (New Rochelle, N) Tj ETQq1 1 0.784314 rgBT /Ov	0.1	0
140	Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2014, 32, 40-40.	0.8	0
141	The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).. Journal of Clinical Oncology, 2017, 35, 22-22.	0.8	0
142	When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 140-140.	0.8	0
143	Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).. Journal of Clinical Oncology, 2019, 37, 262-262.	0.8	0
144	Reply by Authors. Journal of Urology, 2020, 203, 733-733.	0.2	0

#	Article	IF	Citations
145	The effect of day of discharge on hospital readmission after minimally invasive partial nephrectomy.. Canadian Journal of Urology, 2022, 29, 11080-11086.	0.0	0
146	A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1.. Journal of Clinical Oncology, 2022, 40, TPS11586-TPS11586.	0.8	0